Takeda Pharmaceutical Company Limited

XNYS

Last traded price · USD

$21.94

+4.18%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:59 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $21.06
Volume: 480
Day's high: —
Day's low: —

In brief

Takeda Pharmaceutical Company Limited is a US-listed company listed on the New York Stock Exchange, valued at about $70.10B.
Its shares closed at $21.06 on 4 Nov 2026, up 55.3% over the past year.
From India you can buy TAK in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Takeda Pharmaceutical Company Limited (TAK) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole TAK share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade TAK options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

0.8% below its 52-week high
Closed at $21.06 on 4 Nov 2026: 0.8% below the 52-week high of $21.22 (30 Oct 2026) and 55.3% above the low of $13.56 (10 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY over 1 year
1 month: +16.4% (SPY −1.6%). 3 months: +26.0% (SPY −0.4%). 1 year: +55.3% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TAK, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $21.06 was 10.9% above its 50-day average ($19.00) and 19.5% above its 200-day average ($17.62). It has closed above the 200-day for 88 sessions, since 2 Jul 2026. The 50-day average crossed above the 200-day on 10 Aug 2026, 61 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 71.3, 70 or above
The 14-session relative strength index closed at 71.3 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Short interest at 0.1% of shares outstanding
3.3M shares were sold short at the 15 Oct 2026 settlement, 0.1% of the 3.20B shares outstanding; covering them would take 1.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+16.4%

6 months+26.0%

1 year+55.3%

5 years+46.2%

Newswire

About

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.

Website

Notable moves

July 2, 2026
+5.14%
May 8, 2025
−5.25%
October 26, 2023
−7.72%

Takeda Pharmaceutical Company Limited

XNYS

Last traded price · USD

$21.94

+4.18%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:59 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $21.06
Volume: 480
Day's high: —
Day's low: —

In brief

Takeda Pharmaceutical Company Limited is a US-listed company listed on the New York Stock Exchange, valued at about $70.10B.
Its shares closed at $21.06 on 4 Nov 2026, up 55.3% over the past year.
From India you can buy TAK in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Takeda Pharmaceutical Company Limited (TAK) shares from India?

Do I need the price of a whole TAK share to invest?

How much can I invest in US stocks in a year?

Can I trade TAK options or futures?

Insights

Quotes run fifteen minutes behind.

0.8% below its 52-week high
Closed at $21.06 on 4 Nov 2026: 0.8% below the 52-week high of $21.22 (30 Oct 2026) and 55.3% above the low of $13.56 (10 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Ahead of SPY over 1 year
1 month: +16.4% (SPY −1.6%). 3 months: +26.0% (SPY −0.4%). 1 year: +55.3% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: TAK, SPY · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $21.06 was 10.9% above its 50-day average ($19.00) and 19.5% above its 200-day average ($17.62). It has closed above the 200-day for 88 sessions, since 2 Jul 2026. The 50-day average crossed above the 200-day on 10 Aug 2026, 61 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 71.3, 70 or above
The 14-session relative strength index closed at 71.3 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Short interest at 0.1% of shares outstanding
3.3M shares were sold short at the 15 Oct 2026 settlement, 0.1% of the 3.20B shares outstanding; covering them would take 1.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+16.4%

6 months+26.0%

1 year+55.3%

5 years+46.2%

Newswire

About

Website

Notable moves

July 2, 2026
+5.14%
May 8, 2025
−5.25%
October 26, 2023
−7.72%

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited in brief

0.8% below its 52-week high

Ahead of SPY over 1 year

Above its 50- and 200-day averages

RSI(14) at 71.3, 70 or above

Short interest at 0.1% of shares outstanding

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited in brief

0.8% below its 52-week high

Ahead of SPY over 1 year

Above its 50- and 200-day averages

RSI(14) at 71.3, 70 or above

Short interest at 0.1% of shares outstanding